Evaluation of the Additional Effect of Vitix® Gel on Vitiligo Lesions in Patients Treated with Narrow-Band Ultraviolet-B Phototherapy

Sara Rahsepar
Mashhad University of Medical Sciences, Iran

Emadodin Darchini-Maragheh
Mashhad University of Medical Sciences, Iran

Pouran Layegh (Login required)
Mashhad University of Medical Sciences, Iran


Paper #3509 received 18 Jul 2022; revised manuscript received 24 Oct 2022; accepted for publication 27 Oct 2022; published online 15 Dec 2022.

DOI: 10.18287/JBPE22.08.040304

Abstract

Vitiligo is a polygenic acquired skin disorder resulting from the destruction of melanocytes in epidermal cells. Conventional therapeutic options include covering agents, topical corticosteroids, topical immunomodulators, phototherapy with psolaren ultraviolet A (PUVA) and narrowband ultraviolet B (NBUVB). However, successful repigmentation with these modalities is expected only in half of the patients. This study aimed to compare the efficiency of topical Vitix® gel combined with NB-UVB versus NB-UVB alone in the treatment of vitiligo lesions. Thirty patients with vitiligo were enrolled in this study. All patients had relatively symmetrical lesions and received topical Vitix® gel in combination with NB-UVB on one side and NB-UVB alone on the other side. Data were analyzed using Wilcoxon and Mann-Whitney tests. Twenty-five patients completed the course of study (68% female, age: 32.3 ± 13.5 years). Five patients were excluded due to noncompliance to follow-up. The highest treatment response rate was observed in the upper limb’s lesions. However, no statistical difference was observed in patients treated with Vitix® gel combined with NB-UVB versus NB-UVB alone after adjusting for age, sex and lesions’ site (p > 0.05). Significant additional clinical repigmentation was not observed by adding Vitix® gel to NBUVB therapy in treatment of vitiligo lesions.

Keywords

NB-UVB; Treatment; Vitiligo; Vitix®

Full Text:

PDF

References


1. D. J. Gawkrodger, A. D. Ormerod, L. Shaw, I. Mauri-Sole, M. E. Whitton, M. J. Watts, A. V. Anstey, J. Ingham, and K. Young, “Guideline for the diagnosis and management of vitiligo,” British Journal of Dermatology 159(5), 1051–1076 (2008).

2. K. U. Schallreuter, J. Moore, J. M.Wood, W. D. Beazley, D. C. Gaze, D. J.Tobin, H. S. Marshall, A. Panske, E. Panzig, and N. A. Hibberts, “In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase,” Journal of Investigative Dermatology Symposium Proceedings 4(1), 91–96 (1999).

3. K. U. Schallreuter, L. R. Paus, P. Bahadoran, M. Picardo, A. Slominski, Y. E. Elassiuty, E. H. Kemp, C. Giachino, J. D. Liu, R. M. Luiten, and T. Lambe, “Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else?” Experimental Dermatology 17(2), 139–140 (2008).

4. V. Maresca, M. Roccella, F. Roccella, E. Camera, G. D. Porto, S. Passi, P. Grammatico, and M. Picardo, “Increased sensitivity to peroxidative agents as a possible pathogenic factor of melanocyte damage in vitiligo,” Journal of Investigative Dermatology 109(3), 310–313 (1997).

5. S. Hasse, N. C. Gibbons, H. Rokos, L. K. Marles, and K. U. Schallreuter, “Perturbed 6-tetrahydrobiopterin recycling via decreased dihydropteridine reductase in vitiligo: more evidence for H2O2 stress,” Journal of Investigative Dermatology 122(2), 307–313 (2004).

6. K. U. Schallreuter, J. M. Wood, K. R. Lemke, and C. Levenig, “Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients,” Dermatology 190(3), 223–229 (1995).

7. K. U. Schallreuter, J. Moore, S. Behrens‐Williams, A. Panske, and M. Harari, “Rapid initiation of repigmentation in vitiligo with Dead Sea climatotherapy in combination with pseudocatalase (PC-KUS),” International Journal of Dermatology 41(8), 482–487 (2002).

8. W. Westerhof, L. Nieuweboer-Krobotova, “Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A,” Archives of Dermatology 133(12), 1525–1528 (1997).

9. M. L. Dell’Anna, A. Mastrofrancesco, R. Sala, M. Venturini, M. Ottaviani, A. P. Vidolin, G. Leone, P. G. Calzavara, W. Westerhof, and M. Picardo, “Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial,” Clinical and Experimental Dermatology 32(6), 631–636 (2007).

10. T. F. Mohammad, M. Al-Jamal, I. H. Hamzavi, J. E. Harris, G. Leone, R. Cabrera, H. W. Lim, A. G. Pandya, and S. M. Esmat, “The Vitiligo Working Group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo,” Journal of the American Academy of Dermatology 76(5), 879–888 (2017).

11. S. Singh, S. Khandpur, V. K. Sharma, and M. Ramam, “Comparison of efficacy and side-effect profile of oral PUVA vs. oral PUVA sol in the treatment of vitiligo: a 36-week prospective study,” Journal of the European Academy of Dermatology and Venereology 27(11), 1344–1351 (2013).

12. O. Arican, E. B. Kurutas, “Oxidative stress in the blood of patients with active localized vitiligo,” Acta Dermatovenerologica Alpina Panonica Et Adriatica 17(1), 12–16 (2008).

13. P. H. Proctor, E. S. Reynolds, “Free radicals and disease in man,” Physiological Chemistry and Physics and Medical NMR 16(3), 175–195 (1984).

14. M. L. Dell’Anna, S. Urbanelli, A. Mastrofrancesco, E. Camera, P. Iacovelli, G. Leone, P. Manini, M. D’ischia, and M. Picardo, “Alterations of mitochondria in peripheral blood mononuclear cells of vitiligo patients,” Pigment Cell Research 16(5), 553–559 (2003).

15. P. T. Pugliese, “The skin’s antioxidant systems,” Dermatology Nursing 10(6), 401–416 (1998).

16. N. Saha, M. A. Ahmed, A. I. Wasfi, and E. L. Munshid, “Distribution of serum proteins, red cell enzymes and haemoglobins in vitiligo,” Human Heredity 32(1), 46–48 (1982).

17. M. L. Dell’Anna, V. Maresca, S. Briganti, E. Camera, M. Picardo, and M. Falchi, “Mitochondrial impairment in peripheral blood mononuclear cells during the active phase of vitiligo,” Journal of Investigative Dermatology 117(4), 908–913 (2001).

18. E. Hazneci, A. B. Karabulut, C. Ozturk, K. Batcioglu, G. Dogan, S. Karaca, and M. Esrefoglu, “A comparative study of superoxide dismutase, catalase, and glutathione peroxidase activities and nitrate levels in vitiligo patients,” International Journal of Dermatology 44(8), 636–640 (2005).

19. E. M. Shajil, S. Chatterjee, D. Agrawal, T. Bagchi, and R. Begum, “Vitiligo: pathomechanisms and genetic polymorphism of susceptible genes,” Indian Journal of Experimental Biology 44(7), 526–539 (2006).

20. K. U. Schallreuter, H. Rokos, “Vitix®– a new treatment for vitiligo?” International Journal of Dermatology 44(11), 969–970 (2005).

21. K. Kostovic, Z. Pastar, A. Pasic, and R. Eeovic, “Treatment of vitiligo with narrow-band UVB and topical gel containing catalase and superoxide dismutase,” Acta Dermatovenerologica Croatica 15(1), 10–14 (2007).

22. G. Sanclemente, J. J. Garcia, J. J. Zuleta, C. Diehl, C. Correa, and R. Falabella, “A double-blind, randomized trial of 0.05% betamethasone vs. topical catalase/dismutase superoxide in vitiligo,” Journal of the European Academy of Dermatology and Venereology 22(11), 1359–1364 (2008).

23. E. P. Yuksel, F. Aydin, N. Senturk, T. Canturk, and A. Y. Turanli, “Comparison of the efficacy of narrow band ultraviolet B and narrow band ultraviolet B plus topical catalase-superoxide dismutase treatment in vitiligo patients,” European Journal of Dermatology 19(4), 341–344 (2009).

24. D. C. Patel, A. V. Evans, and J. L. Hawk, “Topical pseudocatalase mousse and narrowband UVB phototherapy is not effective for vitiligo: an open, single-centre study,” Clinical and Experimental Dermatology 27(8), 641–644 (2002).




Bookmark and Share


Сontact

34 Moskovskoe shosse, Samara, 443086, Russian Federation
Email: j-bpe@ssau.ru
Phone: +7-846-267-4550
© 2014-2025 J-BPE